Cover Image

The Serum Level of Vascular Endothelial Growth Factor (VEGF) is Declined after Paclitaxel-Carboplatin Combined Chemotherapy Treatment on Epithelial Ovarian Cancer

Show other versions (1)

Objective: To assess the effect of Paclitaxel-Carboplatin combination on epithelial ovarian cancer by studying the changes in VEGF serum levels after receiving 3 series of chemotherapy. Methods: This was a cohort study conducted at several teaching hospitals in Obstetrics and Gynecology Department o...

Full description

Saved in:

Bibliographic Details
Main Author:	Amelia Abdullah (Author)
Format:	Book
Published:	Indonesian Society of Obstetrics and Gynecology, 2012-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Serum Level of Vascular Endothelial Growth Factor (VEGF) is Declined after Paclitaxel-Carboplatin Combined Chemotherapy Treatment on Epithelial Ovarian Cancer
by: Amelia Abdullah
Published: (2012)

Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
by: Huan Wang, et al.
Published: (2022)

Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer
by: Wei-Chun Chen, et al.
Published: (2020)

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
by: Sally Mullany, et al.
Published: (2020)

Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients
by: Zhenhua Du, et al.
Published: (2015)

Vascular endothelial growth factor (VEGF) expression in induction phase chemotherapy of acute lymphoblastic leukemia
by: Dasril Daud, et al.
Published: (2019)

Serum Vascular Endothelial Growth Factor (VEGF) in DMPA Acceptors: Influence on Bleeding Occurrence
by: Ratih Pratiwi, et al.
Published: (2015)

Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor Inhibitors in Health and Disease
by: Sylvain Broussy
Published: (2024)

Survival and Side Effects of Cisplatin/Cyclophosphamide and Carboplatin/Paclitaxel Adjuvant Chemotherapy in Stage IC-IV Ovarian Cancer
by: Unedo H Markus, et al.
Published: (2015)

Lethal Clostridium difficile Colitis Associated with Paclitaxel and Carboplatin Chemotherapy in Ovarian Carcinoma: Case Report and Review of the Literature
by: V. Masciullo, et al.
Published: (2010)

Analysis of the toxicity induced by carboplatin and paclitaxel regimen in ovarian cancer patients
by: Thaís A. GOUVÊA, et al.
Published: (2022)

Comparison of Antiemetic Effects of Ondansetron Granisetron and Tropisetron For Acute Emesis In Ovarian Cancer Patients Receiving Chemotherapy With Paclitaxel and Carboplatin
by: Taner Turan, et al.
Published: (2007)

GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel‐Based Chemotherapy in Ovarian Cancer
by: Amanda Canato Ferracini, et al.
Published: (2021)

Aptamers Versus Vascular Endothelial Growth Factor (VEGF): A New Battle against Ovarian Cancer
by: Yachana Mishra, et al.
Published: (2023)

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
by: Maurie Markman
Published: (2009)

Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?
by: Madison R. Klavans, et al.
Published: (2020)

Front-line chemoimmunotherapy for treating epithelial ovarian cancer: Part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen
by: Szu-Ting Yang, et al.
Published: (2024)

The Effect of Resistance Training on Vascular Endothelial Growth Factor (VEGF) in Older Women
by: Alireza Behjati, et al.
Published: (2015)

Serum Level of Vascular Endothelial Growth Factor (VEGF) can be used to Assess Response of Radiation Therapy in Cervical Cancer
by: Ferry Armanza, et al.
Published: (2014)

Histopathological Efficacy of Docetaxel Versus Paclitaxel As First Line Chemotherapy for Epithelial Ovarian Carcinoma
by: Tayyup Şimşek, et al.
Published: (2008)

Dose-dense regimen versus conventional three-weekly paclitaxel combination with carboplatin chemotherapy in first-line ovarian cancer treatment: a systematic review and meta-analysis
by: Wenjian Gong, et al.
Published: (2023)

The Effect and Mechanism of Vascular Endothelial Growth Factor (VEGF) on Tumor Angiogenesis in Gallbladder Carcinoma
by: Dongqing XU, et al.
Published: (2019)

Recurrent Pseudomembranous Colitis in an Ovarian Cancer Patient Undergoing Carboplatin Chemotherapy
by: Valerie A. Allen, et al.
Published: (2016)

Inflammation of Actinic Keratoses Induced by Combination of Carboplatin and Paclitaxel: Two Case Reports
by: Špela Šuler Baglama, et al.
Published: (2022)

Effects of Interdialytic Weight Gain and Salt Intake on Serum Vascular Endothelial Growth Factor-C (VEGF-C) Levels in Hemodialysis Patients
by: Ercan Türkmen, et al.
Published: (2022)

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy
by: Yue Zhao, et al.
Published: (2018)

Genetic Variant of Vascular Endothelial Growth Factor (VEGF)-A rs699947 is Associated with Preeclampsia
by: Anggelia Puspasari, et al.
Published: (2022)

Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor (VEGF) expression in Sinonasal Inverted Papillomas
by: Mario Bilic, et al.
Published: (2018)

Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients-A Systematic Review and Meta-Analysis
by: Yu Jin Kim, et al.
Published: (2024)

Carboplatin-induced gene expression changes <it>in vitro</it> are prognostic of survival in epithelial ovarian cancer
by: Cannistra Stephen A, et al.
Published: (2008)

A case of metastatic basal cell carcinoma treated with carboplatin and paclitaxel
by: Chryssoula Papageorgiou, et al.
Published: (2023)

Durable remission in a patient with ERBB2-amplified recurrent mucinous ovarian carcinoma treated with Trastuzumab-Carboplatin-Paclitaxel
by: Alexander J. Neil, et al.
Published: (2023)

Vascular endothelial growth factor inhibitors in the treatment of ovarian cancer
by: S. V. Khokhlova
Published: (2014)

PLASMA EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND BASIC FIBROBLAST GROWTH FACTOR (bFGF) IN PATIENTS WITH BRAIN TUMORS.
by: Deyan Handzhiev, et al.
Published: (2015)

Predictive Value of Serum Vascular Endothelial Growth Factor Level for Postoperative Endometriosis Recurrence in Patients with Ovarian Endometriosis
by: Yanfen Zou, et al.
Published: (2023)

Vascular Endothelial Growth Factor-C (VEGF-C) Expression Can Not Predict Pelvic Lymph Node Metastases and Response to Neo-adjuvant Chemotherapy in Bulky Cervical Cancer
by: Johnson Hutapea
Published: (2012)

An Investigation on the Levels of Vascular Endothelial Growth Factor (VEGF) in the Unstimulated Whole Saliva of Patients with Recurrent Aphthous Stomatitis
by: F. Agha-Hosseini, et al.
Published: (2005)

Vascular Endothelial Growth Factor (VEGF-C) Protein Expression Related with Lymphangiogensis in Iraqi Cervical Cancer Patients
by: Yasser kadhim Hashem Al-Zwaini, et al.
Published: (2019)

Proinflammatory Cytokines Increase Vascular Endothelial Growth Factor Expression in Alveolar Epithelial Cells
by: James P. Maloney, et al.
Published: (2015)

Serum Vascular Endothelial Growth Factor Levels and Uterine Fibroid Volume
by: Rajuddin Rajuddin, et al.
Published: (2020)